[go: up one dir, main page]

SE0203654D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0203654D0
SE0203654D0 SE0203654A SE0203654A SE0203654D0 SE 0203654 D0 SE0203654 D0 SE 0203654D0 SE 0203654 A SE0203654 A SE 0203654A SE 0203654 A SE0203654 A SE 0203654A SE 0203654 D0 SE0203654 D0 SE 0203654D0
Authority
SE
Sweden
Prior art keywords
so2r
coor
cor
new compounds
conhr
Prior art date
Application number
SE0203654A
Other languages
Swedish (sv)
Inventor
Elisabet Kallin
Niklas Plobeck
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203654A priority Critical patent/SE0203654D0/en
Publication of SE0203654D0 publication Critical patent/SE0203654D0/en
Priority to TW092133696A priority patent/TW200417546A/en
Priority to ARP030104495A priority patent/AR042316A1/en
Priority to AU2003302919A priority patent/AU2003302919A1/en
Priority to PCT/SE2003/001911 priority patent/WO2004052880A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to new compounds of formula (I) whrein: R<1> is aryl or heteroaryl, each of which is optionally substituted with one or more of R<3>, OR<3>, OCOR<3>, COOR<3>, COR<3>, CONR<3>R<4>, NHCOR<3>, NR<3>R<4>, NHSO2R<3>, SO2R<3>, SO2NR<3>R<4>, SR<3>, CN, halogeno or NO2; R<2> is R<5>, R<6>, COR<5>, COR<6>, CONHR<5>, CONHR<6>, CON(R<6>)2, COOR<5>, COOR<6>, SO2R<5> or SO2R<6>; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
SE0203654A 2002-12-09 2002-12-09 New compounds SE0203654D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0203654A SE0203654D0 (en) 2002-12-09 2002-12-09 New compounds
TW092133696A TW200417546A (en) 2002-12-09 2003-12-01 New compounds
ARP030104495A AR042316A1 (en) 2002-12-09 2003-12-05 NEW COMPOUNDS
AU2003302919A AU2003302919A1 (en) 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use
PCT/SE2003/001911 WO2004052880A1 (en) 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203654A SE0203654D0 (en) 2002-12-09 2002-12-09 New compounds

Publications (1)

Publication Number Publication Date
SE0203654D0 true SE0203654D0 (en) 2002-12-09

Family

ID=20289817

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203654A SE0203654D0 (en) 2002-12-09 2002-12-09 New compounds

Country Status (5)

Country Link
AR (1) AR042316A1 (en)
AU (1) AU2003302919A1 (en)
SE (1) SE0203654D0 (en)
TW (1) TW200417546A (en)
WO (1) WO2004052880A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JP2007511203A (en) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション Diarylurea with kinase inhibitory activity
KR101139557B1 (en) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP5178738B2 (en) 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション Novel JNK inhibitor
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
EP2253618A1 (en) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
EA201290210A1 (en) 2009-11-06 2012-10-30 Плексксикон, Инк. CONNECTIONS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
CA2811479A1 (en) 2010-09-17 2012-03-22 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
EA028821B9 (en) 2011-02-07 2018-10-31 Плексксикон, Инк. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (en) 2011-02-21 2013-09-18 Plexxikon Inc SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
IN2014CN02475A (en) 2011-10-06 2015-06-19 Bayer Ip Gmbh
MX355016B (en) 2011-10-06 2018-04-02 Bayer Ip Gmbh Heterocyclylpyri (mi) dinylpyrazole as fungicidals.
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6482466B2 (en) * 2012-11-03 2019-03-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cytomegalovirus inhibitors
US10202375B2 (en) * 2014-10-08 2019-02-12 Redx Pharma Plc N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
KR102525131B1 (en) 2014-10-08 2023-04-24 레드엑스 파마 피엘씨 N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
CN119350306A (en) * 2018-12-13 2025-01-24 英特维特国际股份有限公司 Preparation method of 1-[(3R, 4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]pyrazole-4-carboxamide
CN115417809A (en) * 2022-09-05 2022-12-02 天津药明康德新药开发有限公司 Preparation method of 4, 4-dipyrrole-2, 2-bipyridine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004012A (en) * 1975-10-14 1977-01-18 Sterling Drug Inc. 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
ES2304797T3 (en) * 1997-12-19 2008-10-16 Amgen Inc. PIRIDINE AND PIRIDAZINE SUBSTITUTED COMPOUNDS AND THEIR PHARMACEUTICAL USE.
ATE407132T1 (en) * 2000-12-05 2008-09-15 Vertex Pharma INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES

Also Published As

Publication number Publication date
WO2004052880A1 (en) 2004-06-24
AU2003302919A1 (en) 2004-06-30
TW200417546A (en) 2004-09-16
AR042316A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
SE0203654D0 (en) New compounds
SE0301963D0 (en) New compounds
SE0200979D0 (en) New compounds
HUP0202248A2 (en) Compounds useful as anti-inflammatory agents
HUP0302345A2 (en) Novel triazolo pyrimidine compounds, their intermediates and process for their preparation
NO20024005D0 (en) Pteridine compounds for the treatment of psoriasis
SE0100569D0 (en) New compounds
NO20033436D0 (en) Mixture and antiviral activity of substituted azaindolo oxoacetic acid piperazine derivatives
HUP0303084A2 (en) 17 beta-carbothioate 17-alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents, process for their preparation and pharmaceutical compositions containing them
AR016762A1 (en) 4-BROMO OR 4-IODINE PHENYLAMINE BENZOHIDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USE OF THE SAME
PA8550101A1 (en) DERIVATIVES OF BENZAMIDA TIAZOL AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS, AND METHODS FOR USE
CA2293382A1 (en) Piperazine derivatives and their use as anti-inflammatory agents
PT1263724E (en) NEW COMPOUNDS
ATE435013T1 (en) HISTONE DEAZETYLASE ENZYME-INHIBITING HYDROXAMIC ACID DERIVATIVES AS NEW ANTI-INFLAMMATORY INHIBITING CYTOKINE SYNTHESIS
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
NO20022470D0 (en) pyrimidine
SE0101322D0 (en) Novel compounds
PA8586801A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
EA200401319A1 (en) NEW HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE IN MEDICINE
ATE440838T1 (en) PHARMACEUTICALLY ACTIVE SULFONYLAMINOSIC ACID DERIVATIVES
ATE368664T1 (en) PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
NO20052794L (en) Antibacterial indoloxazolidinone intermediates for their preparation and pharmaceutical preparations containing them
SE0401655D0 (en) New compounds
ATE253359T1 (en) ANTITHRBOTIC AGENTS